CBP/EP300-IN-1

CAS No. 2443789-32-8

CBP/EP300-IN-1( —— )

Catalog No. M28557 CAS No. 2443789-32-8

CBP/EP300-IN-1 is a CBP/EP300 bromodomain inhibitor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 102 In Stock
2MG 56 In Stock
5MG 93 In Stock
10MG 155 In Stock
25MG 264 In Stock
50MG 365 In Stock
100MG 518 In Stock
200MG 705 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    CBP/EP300-IN-1
  • Note
    Research use only, not for human use.
  • Brief Description
    CBP/EP300-IN-1 is a CBP/EP300 bromodomain inhibitor.
  • Description
    CBP/EP300-IN-1 is a CBP/EP300 bromodomain inhibitor.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Chromatin/Epigenetic
  • Target
    Epigenetic Reader Domain
  • Recptor
    RARα|RARβ
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2443789-32-8
  • Formula Weight
    426.44
  • Molecular Formula
    C23H23FN2O5
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 62.5 mg/mL (146.56 mM)
  • SMILES
    CC(N1C2=CC=C(OC)C=C2C(C(NC3=C(F)C=CC(C(OC(C)(C)C)=O)=C3)=O)=C1)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Jetten AM, et al. New benzoic acid derivatives with retinoid activity: lack of direct correlation between biological activity and binding to cellular retinoic acid binding protein. Cancer Res. 1987 Jul 1;47(13):3523-7.
molnova catalog
related products
  • GNE-064

    GNE-064 is a selective, orally active and highly soluble inhibitor of SMARCA4, SMARCA2 and PBRM1 bromodomains 5.

  • Trotabresib

    Trotabresib (CC-90010) is an orally active inhibitor of BET and can be used in studies about advanced solid tumors.

  • GSK620

    GSK620 is a pan-BD2 inhibitor, which shows an anti-inflammatory phenotype in human whole blood with excellent broad selectivity, developability, and in vivo oral pharmacokinetics.